Eos Energy (EOSE) stock jumps 9% — what to know before Monday’s open

Eos Energy (EOSE) stock jumps 9% — what to know before Monday’s open

New York, January 11, 2026, 09:21 EST — Market closed.

  • Shares of Eos Energy Enterprises jumped roughly 9% Friday, driven by heavy trading volume.
  • The gain outstripped the broader U.S. stock market, which also closed the week at new highs.
  • Traders are eyeing short-interest figures ahead of Tuesday’s U.S. inflation report as Monday gets underway.

Eos Energy Enterprises Inc shares surged almost 9% on Friday, closing at $15.28. Trading in the small-cap battery maker remained volatile heading into the weekend.

The move is significant given Eos’s hefty short position. Investors betting against the stock had borrowed and sold roughly 82.79 million shares as of Dec. 15, according to data from Finviz.

U.S. markets are closed Sunday, leaving investors to wonder if Friday’s rally was just a quick squeeze or the beginning of a bigger move up. Next week, new short-interest data and inflation reports could quickly shift rate expectations, often hitting high-beta stocks hardest.

The broader market showed strength. The S&P 500 hit a record high on Friday following weaker-than-expected U.S. payroll gains for December, and the Russell 2000, tracking smaller firms, climbed 0.8%.

Energy-storage names showed mixed results, leaning mostly higher. Fluence Energy jumped nearly 9%, and Stem climbed around 4%. ESS Tech rose about 2%, while Energy Vault slipped close to 2%.

Eos hasn’t issued any new updates recently. Back in late November, the company completed a $600 million offering of 1.75% convertible senior notes due 2031, along with a registered direct sale of roughly 35.9 million shares priced at $12.78 each. “This was an opportunistic move to strengthen Eos for the scale in front of us,” said interim CFO Nathan Kroeker at the time. (GlobeNewswire)

A filing dated Dec. 22 revealed that board chair Russell Stidolph will step down effective Dec. 31. Joseph Nigro is poised to take over as non-executive chair starting Jan. 1.

Eos produces zinc-based battery energy storage systems designed for storing power over longer periods—typically four hours or more—targeting the long-duration storage market. In its third-quarter earnings, the company posted a record $30.5 million in revenue and stuck to its 2025 revenue forecast of $150 million to $160 million.

Fundamentals, however, still pose significant downside risk. The company posted a net loss of $641.4 million attributable to shareholders for the quarter, largely due to non-cash fair-value adjustments and expenses related to debt retirement. It’s also navigating a manufacturing ramp, where any execution slip-ups could impact cash flow and schedules.

Traders are now eyeing positioning data. FINRA’s calendar sets the next short-interest report for Monday, Jan. 12. Then, on Tuesday, Jan. 13 at 8:30 a.m. ET, the Bureau of Labor Statistics will release December 2025’s Consumer Price Index—a key figure that could shift rate-cut expectations and impact stocks like Eos. (Bls)

Stock Market Today

  • Structure Therapeutics: Can aleniglipron lift the stock in 2026?
    January 11, 2026, 5:26 PM EST. Structure Therapeutics surged after mid-stage data for aleniglipron, a once-daily oral GLP-1 weight-loss candidate. In a 36-week phase 2b study, placebo-adjusted mean weight loss reached 11.3% at the highest dose; higher-dose data suggest up to 15.3%. Tolerability remained within the GLP-1 class norm, with a 10.4% discontinuation rate in the first trial. Management plans a potential phase 3 launch this year while also running a phase 1 for ACCG-2671, an oral amylin-mimetic candidate. Risks loom: regulatory hurdles, and competition from two oral rivals-Wegovy's new oral form and orforglipron-plus a Novo Nordisk pipeline with dual GLP-1/amylin agents. If aleniglipron proves superior, the stock could maintain momentum, but execution risk remains.
OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals
Previous Story

OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

Nvidia stock (NVDA) in focus: first CMO hire, CES self-driving deals and insider sale
Next Story

Nvidia stock (NVDA) in focus: first CMO hire, CES self-driving deals and insider sale

Go toTop